These experiments demonstrate that PD‐L1/EGFR dual inhibitors have promising prospects for immunotherapy.[423] In the treatment of HNSCC, the combination of the EGFR inhibitor erlotinib with an anti‐TGF‐β antibody and celecoxib (a COX‐2 inhibitor) significantly enhances antitumor T cell responses by inhibiting TGF‐β and prostaglandin E2 signaling.[424]. Here, TGFB1 is linked to head and neck squamous cell carcinoma.